The Link Between Human Cytomegalovirus (HCMV) and Hypertension

NCT01113359 | Unknown

• 2 other identifiers: BJCY-CV-2010001YXinchun
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it only replicates in human, an epidemiological study is required to define the relevance of HCMV infection and expression of hcmv-miRNA-UL112 to the pathogenesis of essential hypertension. The investigators found that hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, was highly expressed in the hypertensive patients. Among the top miRNA target predictions, the investigators demonstrate that IRF-1 is a direct target gene of hcmv-miR-UL112, along with MICB that has been previously reported. Both IRF-1 and MICB play critical roles in immuno/inflammatory and anti-infection response. Thus, the investigators speculated that IRF-1 and MICB repression by hcmv-miR-UL112 could be considered a unifying mechanism that evades the host response at several levels: antiviral, inflammatory, and immune. In addition, there is an increasing evidence that IRF-1 may be important in apoptosis, angiogenesis, neointima formation and the pathogenesis of vascular diseases. IRF-1 can up-regulate angiotensin II type 2 receptor (AGTR2) that exerts antiproliferative and proapoptotic actions and affects regulation of blood pressure. It has been reported that the targeted disruption of the mouse AGTR2 gene resulted in a significant increase in blood pressure and increased sensitivity to angiotensin II. The nitric oxide synthase expression and NO synthesis in macrophages and distinct cardiomyocytes are induced and controlled by IRF-1 in response to inflammation, important steps in vascular biology that may improve endothelial function and inhibit smooth muscle cell migration, and a key pathophysiological event in hypertension. Collectively, these reports support a strong relationship between IRF-1 regulation and hypertension, indicating a potential role of hcmv-miR-UL112 and HCMV infection in the pathogenesis of hypertension.Thus, the investigators want to investigate the potential link between HCMV infection and essential hypertension.

Conditions

HCMV Infection; Hypertension

Keywords

HCMV infection; Hypertension; The Potential Link Between HCMV Infection and Essential Hypertension

Outcome Measures

Primary Outcomes (1)

• The positive rate of HCMV infection in hypertensive patients and healthy control

  1 month

Secondary Outcomes (1)

• HCMV copies number per ml plasma of hypertensive patients and healthy controls

  1 month

Study Arms (2)

study group

hypertensive patients

control group

healthy volunteer

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

essential hypertensive patients:

You may qualify if:

• Patients with essential hypertension are assessed for potential secondary causes, for the severity of hypertension, other risk factors and for end-organ damage
• Aged between 30 to 60 years
• Untreated (whole day average \> 140/90 mmHg) or treated hypertension whole-day average \< 140/85), as determined by 24-hour blood pressure monitoring.

You may not qualify if:

• Cancer
• Diabetes
• Smoking
• Renal failure
• Stroke
• Peripheral artery disease

Sponsors & Collaborators

• Beijing Chao Yang Hospital: lead

Study Sites (1)

Jun Cai

Beijing, Chaoyang, 100020, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma

MeSH Terms

Conditions

Cytomegalovirus Infections; Hypertension; Essential Hypertension

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Xin-Chun Yang, MD

  Beijing Chao Yang Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: April 27, 2010
• First Posted: April 29, 2010
• Study Start: April 1, 2010
• Primary Completion: May 1, 2010
• Study Completion: May 1, 2010
• Last Updated: April 29, 2010

Record last verified: 2010-04

Locations

CN (1)